Shionogi & Co.,Ltd. (4507.T) Latest Company News

Sep 2, 2026, 09:26 UTC
Shionogi plans to start a clinical trial in 2027 for its RS virus treatment drug targeting infants under two years old.
Source:
- nikkei.com
Aug 28, 2026, 08:55 UTC
Shionogi announced on August 28 that it received an order from the U.S. government for the antibacterial drug cefiderocol, with payment of $36.9 million (about 5.9 billion yen), under a contract signed in April with BARDA.
Source:
- nikkei.com
Aug 27, 2026, 00:35 UTC
Susmed announced that it has determined a milestone payment of 200 million yen from Shionogi for the milestone achievement of the insomnia app Medcle being covered by insurance at a certain score from June 1, and will record it as business revenue in the first quarter of fiscal year ending June 2027.
Source:
- s.kabutan.jp
- s.kabutan.jp
Aug 27, 2026, 00:35 UTC
Susmed announced the termination of its exclusive sales contract with Shionogi for the insomnia app Medcle, effective via a termination agreement, and will focus on solo sales activities while considering partnerships with other companies.
Source:
Aug 18, 2026, 06:36 UTC
Shionogi & Co. announced it will effectively abolish its mandatory retirement age by extending it to 65 in fiscal 2027 and then renewing employment annually based on performance, allowing employees to continue working indefinitely past 65 as regular employees.
Source:
- nikkei.com
Aug 5, 2026, 00:17 UTC
Shionogi & Co is actively pursuing at least three M&A deals.
Source:
- bloomberg.com
Aug 5, 2026, 00:17 UTC
Shionogi & Co is planning to acquire more manufacturing sites in the US over the next decade.
Source:
- bloomberg.com
Aug 3, 2026, 06:30 UTC
Shionogi reported its Q1 FY2027 (April-June 2026) consolidated net profit of 97.6 billion yen, a 2.5-fold increase year-on-year, with an operating margin improvement to 41.0% from 35.2%.
Source:
Jul 31, 2026, 02:24 UTC
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of the marketed range.
Source:
Jul 29, 2026, 04:52 UTC
Shionogi & Co., Ltd. announced the start of sales of its anti-COVID-19 drug Xocova (ensitrelvir fumaric acid) in the United States.
Source:
- s.kabutan.jp
- s.kabutan.jp
Jun 12, 2026, 07:26 UTC
Chia Tai Tianqing and Shionogi's drug Symproic (naldemedine) was approved for marketing in China by the NMPA for opioid-induced constipation.
Source:
- en.sbpgroup.com

4507.T

Shionogi plans to start a clinical trial in 2027 for its RS virus treatment drug targeting infants under two years old.

Shionogi announced on August 28 that it received an order from the U.S. government for the antibacterial drug cefiderocol, with payment of $36.9 million (about 5.9 billion yen), under a contract signed in April with BARDA.

Susmed announced the termination of its exclusive sales contract with Shionogi for the insomnia app Medcle, effective via a termination agreement, and will focus on solo sales activities while considering partnerships with other companies.

Shionogi & Co. announced it will effectively abolish its mandatory retirement age by extending it to 65 in fiscal 2027 and then renewing employment annually based on performance, allowing employees to continue working indefinitely past 65 as regular employees.

Shionogi & Co is actively pursuing at least three M&A deals.

Shionogi & Co is planning to acquire more manufacturing sites in the US over the next decade.

Shionogi reported its Q1 FY2027 (April-June 2026) consolidated net profit of 97.6 billion yen, a 2.5-fold increase year-on-year, with an operating margin improvement to 41.0% from 35.2%.

Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of the marketed range.

Shionogi & Co., Ltd. announced the start of sales of its anti-COVID-19 drug Xocova (ensitrelvir fumaric acid) in the United States.

Chia Tai Tianqing and Shionogi's drug Symproic (naldemedine) was approved for marketing in China by the NMPA for opioid-induced constipation.